Ligand Pharmaceuticals LGND Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's cash & equivalents?
- Ligand Pharmaceuticals (LGND) reported cash & equivalents of $115.09M in Q1 2026.
- How has Ligand Pharmaceuticals's cash & equivalents changed year-over-year?
- Ligand Pharmaceuticals's cash & equivalents increased by 139.8% year-over-year, from $47.99M to $115.09M.
- What is the long-term trend for Ligand Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's cash & equivalents has grown at a 29.5% compound annual growth rate (CAGR), from $47.96M to $174.93M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.